Primary analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT study

被引：0

作者：

Ueshima, Kazuomi

Kudo, Masatoshi

Tsuchiya, Kaoru

Kato, Naoya

Yamashita, Tatsuya

Shimose, Shigeo

Numata, Kazushi

Kodama, Yuzo

Tanaka, Yasuhito

Kuroda, Hidekatsu

Itoh, Shinji

Aikata, Hiroshi

Hiraoka, Atsushi

Moriguchi, Michihisa

Wada, Yoshiyuki

Nakao, Kazuhiko

Tateishi, Ryosuke

Ogasawara, Sadahisa

Yamamoto, Kouji

Ikeda, Masafumi

机构：

[1] Kindai Univ, Fac Med, Osaka, Osaka, Japan

[2] Kindai Univ, Fac Med, Osaka, Japan

[3] Musashino Red Cross Hosp, Dept Gastroenterol & Hepatol, Musashino, Japan

[4] Chiba Univ, Grad Sch Med, Dept Gastroenterol, Chuo Ku, Chiba, Japan

[5] Kanazawa Univ Hosp, Kanazawa, Japan

[6] Kurume Univ Hosp, Kurume, Japan

[7] Yokohama City Univ, Med Ctr, Yokohama, Japan

[8] Kobe Univ, Div Gastroenterol, Dept Internal Med, Grad Sch Med, Kobe, Japan

[9] Kumamoto Univ, Dept Gastroenterol & Hepatol, Fac Life Sci, Kumamoto, Japan

[10] Iwate Med Univ, Sch Med, Div Gastroenterol & Hepatol, Dept Internal Med, Yahaba, Japan

[11] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka, Japan

[12] Hiroshima Prefectural Hosp, Dept Gastroenterol, Hiroshima, Japan

[13] Ehime Prefectural Cent Hosp, Gastroenterol Ctr, Matsuyama, Japan

[14] Kyoto Prefectural Univ Med, Kyoto, Japan

[15] Natl Hosp Org, Kyushu Med Ctr, Fukuoka, Japan

[16] Nagasaki Univ, Dept Gastroenterol & Hepatol, Grad Sch Biomed Sci, Nagasaki, Japan

[17] Univ Tokyo Hosp, Bunkyo Ku, Tokyo, Japan

[18] Chiba Univ, Grad Sch Med, Chiba, Japan

[19] Yokohama City Univ, Dept Biostat, Sch Med, Yokohama, Japan

[20] Natl Canc Ctr Hosp East, Dept Hepatobiliary & Pancreat Oncol, Kashiwa, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4125

引用

页数：1

共 46 条

[41] ACCRU-GI-2008: A phase II randomized study of atezolizumab (Atezo) plus a multi-kinase inhibitor (MKI) versus MKI alone in patients with unresectable advanced hepatocellular carcinoma (aHCC) who previously received atezolizumab plus bevacizumab (Bev)
Ma, Wen Wee
Ou, Fang-Shu
Li, Jenny Jing
Tran, Nguyen H.
Babiker, Hani M.
Revzin, Alexander
Dong, Haidong
Nelson, Garth D.
Ness, Andrew
Schuster, Carissa E.
Jia, Jingquan
Bekaii-Saab, Tanios S.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[42] REPLACE: A phase III, randomized, open-label trial to evaluate the safety and efficacy of regorafenib and pembrolizumab versus locoregional therapy (LRT) with transarterial chemoembolization (TACE) or transarterial radioembolization (TARE), for the first-line treatment of intermediate-stage hepatocellular carcinoma (HCC) with beyond up-to-7 criteria
Galle, Peter Robert
Kudo, Masatoshi
Llovet, Josep M.
Cheng, Ann-Lii
Lencioni, Riccardo
Oviedo, Yanina
Desai, Kalpna
Monier, Amandine
Finn, Richard S.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[43] IMMUTACE: A biomarker-orientated phase II, single-arm, open-label AIO study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate-stage hepatocellular carcinoma (HCC; AIO-HEP-0217)-Updated efficacy results.
Saborowski, Anna
Waldschmidt, Dirk
Hinrichs, Jan
Ettrich, Thomas Jens
Martens, Uwe Marc
Mekolli, Ardian
De Toni, Enrico N.
Berg, Thomas
Geissler, Michael
Hausner, Guido
Maenz, Martin
Ehmer, Ursula
Kirstein, Marta
Vogel, Arndt
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[44] Hepatic arterial infusion chemotherapy with fine-powder cisplatin and iodized-oil suspension in patients with intermediate-stage and advanced-stage (Barcelona Clinic Liver Cancer stage-B or stage-C) hepatocellular carcinoma: multicenter phase-II clinical study
Takaki, Haruyuki
Yamakado, Koichiro
Tsurusaki, Masakatsu
Yasumoto, Taku
Baba, Yasutaka
Narimatsu, Yoshiaki
Shimohira, Masashi
Yamaguchi, Masato
Matsuo, Kunihiro
Inaba, Yoshitaka
Mikami, Koji
Watanabe, Ryohei
Nishida, Norifumi
Anai, Hiroshi
Kakizawa, Hideaki
Hirota, Shozo
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2015, 20 (04) : 745 - 754
[45] Hepatic arterial infusion chemotherapy with fine-powder cisplatin and iodized-oil suspension in patients with intermediate-stage and advanced-stage (Barcelona Clinic Liver Cancer stage-B or stage-C) hepatocellular carcinoma: multicenter phase-II clinical study
Haruyuki Takaki
Koichiro Yamakado
Masakatsu Tsurusaki
Taku Yasumoto
Yasutaka Baba
Yoshiaki Narimatsu
Masashi Shimohira
Masato Yamaguchi
Kunihiro Matsuo
Yoshitaka Inaba
Koji Mikami
Ryohei Watanabe
Norifumi Nishida
Hiroshi Anai
Hideaki Kakizawa
Shozo Hirota
International Journal of Clinical Oncology, 2015, 20 : 745 - 754
[46] IMbrave150: Exploratory analysis to examine the association between bevacizumab (bev) ever being skipped and bev never being skipped in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) plus bev in a global phase 3 study.
Kudo, Masatoshi
Tsuchiya, Kaoru
Shao, Yu Yun
Finn, Richard S.
Galle, Peter R.
Ducreux, Michel
Cheng, Ann-Lii
Yamashita, Tatsuya
Koga, Hironori
Aoki, Kenichi
Yamada, Kyoko
Asakawa, Takashi
Nakagawa, Yuki
Ikeda, Masafumi
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 538 - 538

← 1 2 3 4 5 →